Compare · CNMD vs MASI
CNMD vs MASI
Side-by-side comparison of CONMED Corporation (CNMD) and Masimo Corporation (MASI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNMD and MASI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.42B, about 8.5x CNMD ($1.11B).
- Over the past year, CNMD is down 37.9% and MASI is up 7.2% - MASI leads by 45.1 points.
- CNMD has been more active in the news (13 items in the past 4 weeks vs 2 for MASI).
- MASI has more recent analyst coverage (24 ratings vs 14 for CNMD).
- Company
- CONMED Corporation
- Masimo Corporation
- Price
- $36.92+7.00%
- $179.96+0.00%
- Market cap
- $1.11B
- $9.42B
- 1M return
- +0.50%
- +0.93%
- 1Y return
- -37.91%
- +7.16%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 1987
- 2007
- News (4w)
- 13
- 2
- Recent ratings
- 14
- 24
CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
Latest CNMD
- CONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Director Bronson David M. converted options into 668 shares, increasing direct ownership by 4% to 17,909 units (SEC Form 4)
- Director Council Laverne H converted options into 668 shares, increasing direct ownership by 17% to 4,716 units (SEC Form 4)
- SEC Form 4 filed by Director Kelderman Kim
- Director Farkas Charles converted options into 668 shares, increasing direct ownership by 4% to 15,527 units (SEC Form 4)
- Director Kaye Mark converted options into 668 shares, increasing direct ownership by 439% to 820 units (SEC Form 4)
- Director Schwarzentraub Barbara J converted options into 668 shares, increasing direct ownership by 15% to 5,012 units (SEC Form 4)
- Amendment: New insider Lockwood Kimberly claimed ownership of 1,868 shares (SEC Form 3)
- New insider Lockwood Kimberly claimed ownership of 1,868 shares (SEC Form 3)
- CONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
Latest MASI
- Sirius XM Holdings Set to Join S&P MidCap 400
- SEC Form SD filed by Masimo Corporation
- SEC Form SCHEDULE 13G filed by Masimo Corporation
- SEC Form 10-Q filed by Masimo Corporation
- Director Scannell Timothy J converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Director Lane Wendy E converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Chairman of the Board Brennan Michelle converted options into 1,225 shares, increasing direct ownership by 17% to 8,543 units (SEC Form 4)
- Chief Human Resources Officer Hellmann Elisabeth A converted options into 335 shares and covered exercise/tax liability with 121 shares (SEC Form 4) to satisfy tax liability
- Masimo Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- Masimo Shareholders Approve Acquisition by Danaher